Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon3.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-GBP1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The target known commonly as GBP1 or guanylate-binding protein 1 plays a mechanical role as a large GTPase with a molecular mass of approximately 67 kDa. This protein is expressed in various tissues most notably in interferon-gamma-induced human cells. GBP1 localizes mainly in the cytoplasm and associates with cellular membranes. Alternate designations for the GBP1 protein include GBP 1. Its role as a GTPase involves hydrolyzing GTP which is critical for its cellular functions.
Biological function summary
The GBP1 protein supports cellular defense mechanisms against pathogens such as viruses and bacteria. GBP1 participates in the hydrolysis of GTP to GMP an action that influences its anti-pathogenic effects. It is a member of the interferon-inducible large GTPase family and can form oligomeric complexes enhancing its antiviral and antimicrobial activity. It interacts with various proteins linked to innate immunity and contributes to modulating the immune response.
Pathways
GBP1 is involved in pathways linked to interferon signaling and innate immunity. The protein plays a significant role in the JAK-STAT signaling pathway where it exerts its antiviral effects. GBP1 interacts closely with other proteins such as STAT1 and is responsive to interferon signals influencing gene expression and immune responses. Its activity in these pathways is critical for mounting an effective defense against infections.
GBP1 has been associated with inflammatory diseases and cancer. The protein's expression levels often increase in response to inflammatory signals implicating it in the pathogenesis of diseases like Crohn's disease. Moreover GBP1 has a connection with cancer-related mechanisms where it might affect tumor cell proliferation. In these contexts proteins such as STAT1 and other interferon-responsive proteins relate closely to the function and regulatory mechanisms of GBP1.
